Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases

Table 3

The incidence of hepatotoxicity caused by EGFR-TKIs.

Study name	Incidence of hepatotoxicity; Any grade	Grade 3, 4	Ratio of patients with 　EGFR gene mutation	Ethnicity/race	Number of patients who administrate EGFR-TKIs	References
Gefitinib
V15-32	24.2%	11.1%	54.%	Japanese	244	Maruyama et al. [13]
IPASS		9.4%	21.7%	Asian	607	Mok et al. [14]
NEJ002	55.3%	26.3%	100%	Japanese	114	Maemondo et al. [5]
WJTOG3405	70.1%	24%		Japanese	177	Mitsudomi et al. [6]
Erlotinib
Phase II study in Japan	24.2%	3.2%	Not described	Japanese	62	Kubota et al. [20]
OLCSG trial 0705	30%	0%	0%	Japanese	30	Yoshioka et al. [21]
Trust	<1%	<1%	Not described	White, Asian, Black	6580	Reck et al. [22]

Abbreviations: EGFR: epidermal growth factor receptor; TKIs: tyrosine kinase inhibitors.